Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol

M. C. Mauri; V. Laini; C. P C Steinhilber; L. Boscati

Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol

M. C. Mauri, V. Laini, C. P C Steinhilber, L. Boscati

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.

Original language	English
Pages (from-to)	59-63
Number of pages	5
Journal	New Trends in Experimental and Clinical Psychiatry
Volume	14
Issue number	1
Publication status	Published - 1998

Keywords

Depressive
Haloperidol dosages
Negative-positive symptoms
Schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol'. Together they form a unique fingerprint.

Cite this

@article{fbe54838268440678c7013c8c98dcb36,

title = "Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol",

abstract = "81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.",

keywords = "Depressive, Haloperidol dosages, Negative-positive symptoms, Schizophrenia",

author = "Mauri, {M. C.} and V. Laini and Steinhilber, {C. P C} and L. Boscati",

year = "1998",

language = "English",

volume = "14",

pages = "59--63",

journal = "New Trends in Experimental and Clinical Psychiatry",

issn = "0393-5310",

publisher = "CIC Edizioni Internazionali s.r.l.",

number = "1",

}

TY - JOUR

T1 - Depressive, negative and positive symptoms in schizophrenia

T2 - Response to different dosages of haloperidol

AU - Mauri, M. C.

AU - Laini, V.

AU - Steinhilber, C. P C

AU - Boscati, L.

PY - 1998

Y1 - 1998

N2 - 81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.

AB - 81 chronic schizophrenic in-patients during a riexacerbation phase, were included into the study. The patients were treated with HL from 1.50 to 18.00 mg p.o., t.i.d. No significant correlations were found among HRSD, SANS and SAPS. All the patients showed a significant amelioration at BPRS, HRSD, SAPS and SANS at the HL dosage below 0.2 mg/kg (<8.5 mg/die), while at the dosage up to 0.2 mg/kg (≤ 14.8 mg/die), they showed an amelioration only at BPRS and SAPS. Upper dosages of HL seem to show their efficacy on productive symptoms, while the efficacy on negative and depressive symptoms appeared only at lower dosages.

KW - Depressive

KW - Haloperidol dosages

KW - Negative-positive symptoms

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0031842724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031842724&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031842724

VL - 14

SP - 59

EP - 63

JO - New Trends in Experimental and Clinical Psychiatry

JF - New Trends in Experimental and Clinical Psychiatry

SN - 0393-5310

IS - 1

ER -

Depressive, negative and positive symptoms in schizophrenia: Response to different dosages of haloperidol

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this